• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    50 Stocks Moving In Monday's Mid-Day Session

    3/14/22 12:06:08 PM ET
    $ACMR
    $AEI
    $AGRI
    $AHPI
    Industrial Machinery/Components
    Technology
    Real Estate
    Finance
    Get the next $ACMR alert in real time by email

    Gainers

    • Volt Information Sciences, Inc. (NYSE:VOLT) shares jumped 95.2% to $5.89 after the company announced it would be acquired for $6 per share.
    • AgriFORCE Growing Systems, Ltd. (NASDAQ:AGRI) shares climbed 36.5% to $4.3001.
    • Turquoise Hill Resources Ltd. (NYSE:TRQ) gained 32.4% to $26.68 after Rio Tinto proposed to acquire the company at C$34 per share.
    • Mullen Automotive, Inc. (NASDAQ:MULN) rose 27% to $1.7153 after jumping 26% on Friday.
    • Molecular Data Inc. (NASDAQ:MKD) rose 25.2% to $0.1930 after dropping around 12% on Friday.
    • Alset EHome International Inc. (NASDAQ:AEI) shares rose 20.2% to $0.5168 after jumping 24% on Friday.
    • Moderna, Inc. (NASDAQ:MRNA) gained 18.9% to $164.29 after the company announced the first participant has been dosed in a clinical trial of an experimental HIV trimer mRNA vaccine.
    • BioNTech SE (NASDAQ:BNTX) jumped 16.7% to $158.32. The Pfizer- BioNTech vaccine is only moderately effective against the omicron variant when tested in children ages 5 to 15. According to a study conducted by the Centers for Disease Control and Prevention (CDC) and Abt Associates, the shot showed 59% efficacy in those ages 12 to 15 and 31% in those ages 5 to 11.
    • Sonendo, Inc. (NYSE:SONX) surged 16% to $3.62. Sonendo is expected report financial results for the fourth quarter on Wednesday, March 23, 2022.
    • Arqit Quantum Inc. (NASDAQ:ARQQ) gained 15.6% to $14.71.
    • Art's-Way Manufacturing Co., Inc. (NASDAQ:ARTW) surged 15% to $6.62.
    • Allied Healthcare Products, Inc. (NASDAQ:AHPI) jumped 14.1% to $2.92.
    • Knightscope, Inc. (NASDAQ:KSCP) jumped 13.9% to $5.78 after the company announced a new commercial developer contract.
    • Hour Loop, Inc. (NASDAQ:HOUR) gained 12.9% to $2.8450.
    • Paramount Global (NASDAQ:PARA) surged 12.3% to $36.37.
    • AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) jumped 11.9% to $4.23 following Q4 results.
    • Signet Jewelers Limited (NYSE:SIG) gained 10.8% to $72.89. Signet Jewelers suspended business interaction with Russian-owned entities, Reuters reported.
    • Novavax, Inc. (NASDAQ:NVAX) surged 10.2% to $80.47. Strength is possibly due to a spike in COVID-19 cases in China, which could lift vaccine sector sentiment.
    • Ra Medical Systems, Inc. (NYSE:RMED) rose 9.5% to $0.4490.
    • 36Kr Holdings Inc. (NASDAQ:KRKR) rose 6.8% to $0.6833. Dagang Feng disclosed a 30.6% active stake in 36Kr Holdings.


    Losers

    • Nektar Therapeutics (NASDAQ:NKTR) shares dipped 54.7% to $4.8150 after the company's Phase 3 PIVOT trial did not meet its primary endpoint.
    • Kingsoft Cloud Holdings Limited (NASDAQ:KC) fell 34.2% to $3.23. JP Morgan downgraded Kingsoft Cloud from Neutral to Underweight and announced a $3.5 price target.
    • Waitr Holdings Inc. (NASDAQ:WTRH) fell 30.7% to $0.3161. Waitr Hldgs posted a Q4 adjusted loss of $0.04 per share.
    • Avinger, Inc. (NASDAQ:AVGR) shares fell 26.3% to $0.1801.
    • MultiPlan Corporation (NYSE:MPLN) fell 25.2% to $3.6650.
    • Lilium N.V. (NASDAQ:LILM) dipped 23.8% to $2.8099.
    • Zhihu Inc. (NYSE:ZH) fell 22.7% to $1.63 after the company reported worse-than-expected Q4 EPS results.
    • ACM Research, Inc. (NASDAQ:ACMR) fell 22.2% to $43.85.
    • I-Mab (NASDAQ:IMAB) fell 20.2% to $13.36.
    • Excellon Resources Inc. (NYSE:EXN) shares fell 19.6% to $1.11 after surging 40% on Friday.
    • VNET Group, Inc. (NASDAQ:VNET) fell 18.8% to $3.8650.
    • Dada Nexus Limited (NASDAQ:DADA) dropped 18.3% to $5.76. JP Morgan downgraded Dada Nexus from Overweight to Neutral and announced a $7.5 price target.
    • Sentage Holdings Inc. (NASDAQ:SNTG) fell 17.4% to $1.0310.
    • Gracell Biotechnologies Inc. (NASDAQ:GRCL) dropped 16.7% to $2.12 following Q4 results.
    • iQIYI, Inc. (NASDAQ:IQ) dropped 15.8% to $2.34 after JP Morgan downgraded the stock from Overweight to Underweight and announced a $2 price target.
    • Ramaco Resources, Inc. (NASDAQ:METC) fell 15.5% to $16.72.
    • AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) shares fell 14.9% to $0.67 after jumping over 15% on Friday.
    • Apyx Medical Corporation (NASDAQ:APYX) fell 14.6% to $8.45. Apyx Medical received notification of pending FDA medical device safety communication related to its advanced energy products.
    • Peabody Energy Corporation (NYSE:BTU) dropped 14.4% to $19.69.
    • Shineco, Inc. (NASDAQ:SISI) shares fell 14.4% to $3.33.
    • Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) dropped 14.2% to $4.80.
    • Houston American Energy Corp. (NYSE:HUSA) fell 14% to $5.70 after dropping 22% on Friday.
    • Hello Group Inc. (NASDAQ:MOMO) dropped 13.7% to $5.74. JP Morgan downgraded Hello Group from Overweight to Neutral and announced a $7 price target.
    • VOC Energy Trust (NYSE:VOC) fell 11.2% to $6.42.
    • GDS Holdings Limited (NASDAQ:GDS) fell 10.8% to $24.40 after dipping 20% on Friday.
    • Solid Biosciences Inc. (NASDAQ:SLDB) fell 9.7% to $0.9574 after jumping 37% on Friday.
    • Imperial Petroleum Inc. (NASDAQ:IMPP) fell 9.3% to $3.2740 after dipping 28% on Friday.
    • Marine Petroleum Trust (NASDAQ:MARPS) fell 8.7% to $9.94 after dipping 23% on Friday.
    • Pintec Technology Holdings Limited (NASDAQ:PT) fell 8.7% to $0.5251.
    • OceanPal Inc. (NASDAQ:OP) fell 7.4% to $0.6850. OceanPal reported the receipt of Nasdaq notice.
    Get the next $ACMR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACMR
    $AEI
    $AGRI
    $AHPI

    CompanyDatePrice TargetRatingAnalyst
    BioNTech SE
    $BNTX
    2/2/2026$113.00Outperform → Market Perform
    Leerink Partners
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    Ramaco Resources Inc.
    $METC
    1/20/2026$30.00Hold → Buy
    Jefferies
    BioNTech SE
    $BNTX
    1/16/2026$142.00Neutral → Buy
    Goldman
    Moderna Inc.
    $MRNA
    1/7/2026$34.00Neutral
    UBS
    Apyx Medical Corporation
    $APYX
    12/16/2025$6.00Buy
    Roth Capital
    Moderna Inc.
    $MRNA
    12/12/2025$30.00Hold
    Jefferies
    Signet Jewelers Limited
    $SIG
    12/11/2025$96.00Neutral
    Goldman
    More analyst ratings

    $ACMR
    $AEI
    $AGRI
    $AHPI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Welch David Ryan was granted 97,410 shares and bought $1,424 worth of shares (11 units at $129.42), increasing direct ownership by 647% to 97,421 units (SEC Form 4)

    4 - AGRIFORCE GROWING SYSTEMS LTD. (0001826397) (Issuer)

    9/30/25 7:56:59 PM ET
    $AGRI
    Metal Fabrications
    Industrials

    Chief Executive Officer Chan Heng Fai Ambrose bought $42,527 worth of shares (33,000 units at $1.29), increasing direct ownership by 0.10% to 31,822,903 units (SEC Form 4)

    4 - Alset Inc. (0001750106) (Issuer)

    8/19/25 4:15:23 PM ET
    $AEI
    Real Estate
    Finance

    Amendment: Large owner Bower Family Holdings, Llc bought 3,066,580 shares, increasing direct ownership by 1,407% to 3,284,598 units (SEC Form 4)

    4/A - HOUSTON AMERICAN ENERGY CORP (0001156041) (Issuer)

    7/23/25 4:15:19 PM ET
    $HUSA
    Oil & Gas Production
    Energy

    $ACMR
    $AEI
    $AGRI
    $AHPI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026

    SAN FRANCISCO, Feb. 9, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on the development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week maintenance period of the ongoing Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for moderate-to-severe atopic dermatitis on Tuesday, February 10, 2026 at 8:00 am ET / 5:00 am PT.  Conference Call The results will be provided in a mo

    2/9/26 4:15:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACM Research to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026

    FREMONT, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ACM Research, Inc. ("ACM") (NASDAQ:ACMR) announced today that it will release its financial results for the fourth quarter and fiscal year 2025 before the U.S. market open on Thursday, February 26, 2026. ACM will conduct a corresponding conference call at 8:00 a.m. U.S. Eastern Time (9:00 p.m. China Time) to discuss the results. What:ACM Fourth Quarter and Fiscal Year (ended December 31, 2025) Earnings CallWhen:8:00 a.m. U.S. Eastern Time on Thursday, February 26, 2026Webcast:ir.acmr.com/news-events/events   To join the conference call via telephone, participants must use the following link to complete an online registration process. Upon

    2/9/26 4:05:00 PM ET
    $ACMR
    Industrial Machinery/Components
    Technology

    Imperial Petroleum Announces $10 Million Share Repurchase Program

    ATHENS, Greece, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Imperial Petroleum Inc. (NASDAQ:IMPP) (the "Company") today announced that its Board of Directors has approved a share repurchase program and authorized the officers of the Company to repurchase, from time to time, up to $10,000,000 of the Company's common stock. Shares may be purchased in open market or privately negotiated transactions, at times and prices that are considered to be appropriate by the Company, and the program may be suspended or discontinued at any time. About Imperial Petroleum Inc. IMPERIAL PETROLEUM INC. is a ship-owning company providing petroleum products, crude oil and drybulk seaborne transportation services. The

    2/9/26 9:20:00 AM ET
    $IMPP
    Marine Transportation
    Consumer Discretionary

    $ACMR
    $AEI
    $AGRI
    $AHPI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    October 3, 2023 - FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants

    For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO

    10/3/23 2:56:27 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ACMR
    $AEI
    $AGRI
    $AHPI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BioNTech downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded BioNTech from Outperform to Market Perform and set a new price target of $113.00

    2/2/26 6:48:45 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays resumed coverage on Moderna with a new price target

    Barclays resumed coverage of Moderna with a rating of Equal Weight and set a new price target of $25.00

    1/28/26 7:18:07 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ramaco Resources upgraded by Jefferies with a new price target

    Jefferies upgraded Ramaco Resources from Hold to Buy and set a new price target of $30.00

    1/20/26 8:45:53 AM ET
    $METC
    Coal Mining
    Energy

    $ACMR
    $AEI
    $AGRI
    $AHPI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Howton David T sold $121,713 worth of shares (18,894 units at $6.44), decreasing direct ownership by 16% to 97,859 units (SEC Form 4)

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    2/6/26 6:05:06 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Cumbo Alexander sold $315,093 worth of shares (48,913 units at $6.44), decreasing direct ownership by 18% to 222,018 units (SEC Form 4)

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    2/6/26 6:01:54 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Ganot Ilan sold $46,414 worth of shares (7,205 units at $6.44) (SEC Form 4)

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    2/6/26 6:01:49 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACMR
    $AEI
    $AGRI
    $AHPI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.

    SCHEDULE 13G/A - Moderna, Inc. (0001682852) (Subject)

    2/9/26 10:48:12 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Imperial Petroleum Inc.

    6-K - Imperial Petroleum Inc./Marshall Islands (0001876581) (Filer)

    2/9/26 9:23:26 AM ET
    $IMPP
    Marine Transportation
    Consumer Discretionary

    SEC Form SCHEDULE 13G filed by Novavax Inc.

    SCHEDULE 13G - NOVAVAX INC (0001000694) (Subject)

    2/9/26 7:56:48 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACMR
    $AEI
    $AGRI
    $AHPI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Arqit Quantum Inc.

    SC 13D/A - Arqit Quantum Inc. (0001859690) (Subject)

    12/13/24 8:03:28 PM ET
    $ARQQ
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by Arqit Quantum Inc.

    SC 13D/A - Arqit Quantum Inc. (0001859690) (Subject)

    12/10/24 8:05:26 PM ET
    $ARQQ
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by iQIYI Inc.

    SC 13D/A - iQIYI, Inc. (0001722608) (Subject)

    12/4/24 8:11:53 AM ET
    $IQ
    Consumer Electronics/Video Chains
    Consumer Discretionary

    $ACMR
    $AEI
    $AGRI
    $AHPI
    Financials

    Live finance-specific insights

    View All

    Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026

    SAN FRANCISCO, Feb. 9, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on the development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week maintenance period of the ongoing Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for moderate-to-severe atopic dermatitis on Tuesday, February 10, 2026 at 8:00 am ET / 5:00 am PT.  Conference Call The results will be provided in a mo

    2/9/26 4:15:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACM Research to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026

    FREMONT, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ACM Research, Inc. ("ACM") (NASDAQ:ACMR) announced today that it will release its financial results for the fourth quarter and fiscal year 2025 before the U.S. market open on Thursday, February 26, 2026. ACM will conduct a corresponding conference call at 8:00 a.m. U.S. Eastern Time (9:00 p.m. China Time) to discuss the results. What:ACM Fourth Quarter and Fiscal Year (ended December 31, 2025) Earnings CallWhen:8:00 a.m. U.S. Eastern Time on Thursday, February 26, 2026Webcast:ir.acmr.com/news-events/events   To join the conference call via telephone, participants must use the following link to complete an online registration process. Upon

    2/9/26 4:05:00 PM ET
    $ACMR
    Industrial Machinery/Components
    Technology

    Peabody Reports Results for the Quarter and Year Ended December 31, 2025

    Key Operational and Financial Metrics Meet or Exceed 2025 Full-Year Guidance Centurion Longwall Mining Ahead of Schedule U.S. Policy and Market Tailwinds Supportive of Increasing Coal Use ST. LOUIS, Feb. 5, 2026 /PRNewswire/ -- Peabody (NYSE:BTU) today reported fourth quarter net income attributable to common stockholders of $10.4 million, or $0.09 per diluted share, compared to $30.6 million, or $0.25 per diluted share, in the prior year quarter. Peabody had Adjusted EBITDA1 of $118.1 million in the fourth quarter of 2025, compared to $176.7 million in the fourth quarter of 2024. Full-year 2025 revenue totaled $3,861.5 million compared to $4,236.7 million in the prior year in the face of s

    2/5/26 7:46:00 AM ET
    $BTU
    Coal Mining
    Energy

    $ACMR
    $AEI
    $AGRI
    $AHPI
    Leadership Updates

    Live Leadership Updates

    View All

    BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

    Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer ("CPO") effective March 1, 2026. The appointment is in line with BioNTech's strategy to become a multi-product oncology company by 2030 and underscores the importance of its global, highly skilled workforce in achieving this objective. In the newly created Management Board role, Kylie Jimenez will be responsible for shaping and leading BioNTech's people strategy and its execution in alignment with the Company's priorities and business goals. She will focus on attractin

    1/28/26 8:00:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Houston American Energy Corp. Reports Preliminary, Unaudited Results for Third Quarter 2025

    HOUSTON, TX, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Houston American Energy Corp. (NYSE:HUSA) ("HUSA" or the "Company") today announced preliminary, unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Preliminary, Unaudited Results Preliminary, total operating expenses for the third quarter 2025 are expected to be approximately $3.8 million, an increase of $2.7 million compared to the second quarter 2025 reflecting the operating costs of the number of the combined organization following the acquisition on July 1, 2025, as well as the additional costs of integration. The increased cost also reflects a number of initiatives undertaken in the quarter:

    11/10/25 8:30:00 AM ET
    $HUSA
    Oil & Gas Production
    Energy